Name: UMIN ID:
Unique ID issued by UMIN | UMIN000007940 |
---|---|
Receipt number | R000009350 |
Scientific Title | Randomized Phase II trial of Docetaxel treatment vs Paclitaxel Treatment for advanced/metastatic esophageal cancer resistant to fluoropyrimidine and/or platinum compound (OGSG1201) |
Date of disclosure of the study information | 2012/05/14 |
Last modified on | 2022/11/06 00:40:13 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/05/13 22:40:02 | ||
2 | Update | 2012/06/24 21:56:20 | Organization Organization Organization1 Email1 |
|
3 | Update | 2012/06/24 22:14:28 | Acronym |
|
4 | Update | 2012/06/24 22:15:59 | Organization Division name Address |
|
5 | Update | 2012/06/24 22:23:42 | Public title Public title |
|
6 | Update | 2012/11/15 01:10:12 | Last follow-up date Date analysis concluded |
|
7 | Update | 2013/05/15 21:30:39 | Anticipated trial start date |
|
8 | Update | 2014/11/15 14:22:23 | TEL TEL Institutions |
|
9 | Update | 2015/05/13 23:10:41 | Email Institutions |
|
10 | Update | 2015/11/18 00:07:30 | Key inclusion criteria Key inclusion criteria |
|
11 | Update | 2015/11/18 00:09:28 | Last follow-up date |
|
12 | Update | 2016/05/17 00:25:24 | Name of primary person or sponsor Organization |
|
13 | Update | 2017/06/26 23:37:00 | Organization Organization Address Address TEL Organization Organization Address Address TEL |
|
14 | Update | 2017/06/26 23:40:01 | Key inclusion criteria |
|
15 | Update | 2017/06/26 23:41:13 | Last follow-up date |
|
16 | Update | 2017/11/16 22:50:08 | Institutions |
|
17 | Update | 2018/04/30 23:46:29 | Email |
|
18 | Update | 2018/05/10 20:32:14 | Email |
|
19 | Update | 2018/05/27 17:09:48 | Last follow-up date |
|
20 | Update | 2018/08/01 21:52:33 | UMIN ID1 |
|
21 | Update | 2018/08/01 21:57:02 | Name of person sending information Name of person sending information Organization Organization Division name Division name Address Address TEL Institutions |
|
22 | Update | 2020/01/05 18:25:04 | Recruitment status Date of IRB Last follow-up date |
|
23 | Update | 2020/01/22 22:17:47 | Date of IRB |
|
24 | Update | 2021/05/20 12:43:05 | Recruitment status Date analysis concluded |
|
25 | Update | 2021/05/20 12:47:25 | Number of participants that the trial has enrolled Results Delayed Results Delay Reason Results Delay Reason |
|
26 | Update | 2022/11/05 18:58:10 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Results Delayed Results Delay Reason Results Delay Reason Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
27 | Update | 2022/11/06 00:40:13 | Baseline Characteristics Baseline Characteristics |